Last week, I wrote an article detailing how Crescent Point Energy Corporation (CPG) not only has perhaps the most economic collection of assets in Canada on a profit-investment ratio basis but is also the most undervalued in its peer group on a 2018 EV/DACF basis. However, in order for undervaluation to be resolved, investors need to care. After two dividend cuts and a poorly communicated large equity financing (immediately after a new commitment to organic growth), Crescent Point has soured relations with both institutional and retail investors.
The company, however, has multiple upside catalysts that could serve to restore investor interest in the stock and remedy its chronic undervaluation. These catalysts should play out over the next 12 months, and the upside for Crescent Point is substantial given where it is trading relative to its peers and its own historical valuation:
Top Undervalued Stocks To Own Right Now: First BanCorp.(FBP)
Advisors' Opinion:- [By Ethan Ryder]
First Bancorp (NYSE:FBP) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Friday.
- [By Logan Wallace]
Press coverage about First BanCorp (NYSE:FBP) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. First BanCorp earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the bank an impact score of 47.5369094230747 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Logan Wallace]
Prudential Financial Inc. lessened its position in First BanCorp (NYSE:FBP) by 16.5% in the first quarter, Holdings Channel reports. The institutional investor owned 906,869 shares of the bank’s stock after selling 179,820 shares during the period. Prudential Financial Inc.’s holdings in First BanCorp were worth $5,459,000 at the end of the most recent quarter.
- [By Ethan Ryder]
Voya Investment Management LLC lowered its position in First Bancorp (NYSE:FBP) by 83.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 400,520 shares of the bank’s stock after selling 1,959,886 shares during the period. Voya Investment Management LLC owned approximately 0.19% of First Bancorp worth $3,064,000 as of its most recent SEC filing.
Top Undervalued Stocks To Own Right Now: Rigel Pharmaceuticals Inc.(RIGL)
Advisors' Opinion:- [By Maxx Chatsko]
Shares of Rigel Pharmaceuticals (NASDAQ:RIGL) climbed over 17% today after the company announced second-quarter and first-half 2018 earnings results. The pharma company reported $1.8 million in net product sales of Tavalisse, the portfolio's first approved product, during the most recent quarter. That may not seem like much, but not when you consider that the chronic immune thrombocytopenia (ITP) treatment only launched on May 29.
- [By Cory Renauer]
Here's why analysts are willing to stick their necks out and predict huge gains ahead for these fledgling drugmakers. Just remember, huge potential rewards usually come with a great deal of risk.
Company (Symbol) Bank Recent Price Target Implied Upside at Recent Prices Tocagen Inc. (NASDAQ:TOCA) Citigroup $27 141% Vital Therapies, Inc. (NASDAQ:VTL) Cantor Fitzgerald $18 142% Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Citigroup $8.50156%
- [By Trey Thoelcke]
Here too, the low price makes this stock an attractive target. Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
- [By Trey Thoelcke]
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) saw its CEO and president, Raul Rodriguez, pick up 114,000 shares last week. The average share price was $2.63, and the transaction totaled about $300,000. The buy followed a quarterly report that surprised to the upside on revenues. The stock thus far is trading around 7% higher than the CEO’s purchase price.
Top Undervalued Stocks To Own Right Now: Compugen Ltd.(CGEN)
Advisors' Opinion:- [By Ethan Ryder]
Headlines about Compugen (NASDAQ:CGEN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Compugen earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.9719981987303 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Chris Lange]
Compugen Ltd. (NASDAQ: CGEN) shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb Co. (NYSE: BMY) will make a $12 million equity investment as part of its collaboration on a cancer trial.
- [By Joseph Griffin]
Compugen (NASDAQ:CGEN) – Equities researchers at Jefferies Group increased their Q2 2018 earnings estimates for shares of Compugen in a research note issued on Wednesday, May 9th. Jefferies Group analyst P. Welford now anticipates that the biotechnology company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.21). Jefferies Group also issued estimates for Compugen’s Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($1.00) EPS, FY2020 earnings at ($1.19) EPS, FY2021 earnings at ($1.37) EPS and FY2022 earnings at ($1.58) EPS.
- [By Joseph Griffin]
News headlines about Compugen (NASDAQ:CGEN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.0723272283748 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
No comments:
Post a Comment